Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Humacyte (HUMA) Stock Price & Analysis

1,738 Followers

HUMA Stock Chart & Stats

$0.45$0.05(13.42%)
At close: 4:00 PM EST
$0.4$0.5$0.6$0.7Aug 10Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2
Day’s Range
$0.40 - $0.45
52-Week Range
$0.34 - $1.53
Previous Close
$0.40
Volume
N/A
Average Volume (3M)
5.74M
Market Cap
$124.51M
Enterprise Value
$168.89M
Total Cash (Recent Filing)
$79.90M
Total Debt (Recent Filing)
$66.18M
Price to Earnings (P/E)
―
Beta
3.09
Next Earnings
Nov 10, 2026 (Est.)
EPS Estimate
-0.1
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Clinical And Regulatory Progress

The statistically significant interim result supports ATEV’s clinical differentiation in dialysis access, while the planned supplemental BLA and priority-review request provide a defined regulatory pathway. Together, these milestones can support broader adoption and future commercialization over the next several quarters.

Early Commercial Adoption

Adoption across major health systems indicates that commercialization is progressing beyond isolated sales and creates a potential base for repeat utilization. The rebuilt commercial organization and national-account strategy could improve market access as the company expands physician and hospital engagement.

Platform Expansion

CTEV extends Humacyte’s tissue-engineering platform into coronary bypass applications, broadening the potential product pipeline beyond dialysis access. FDA acceptance of the IND and completed commercial-scale lot reduce key development hurdles and establish a path toward clinical validation.

Bears Say

Persistent Losses And Cash Burn

Large ongoing losses and deeply negative operating and free cash flow show that current commercial activity is not yet funding the business. Continued clinical development, manufacturing, and selling costs may require additional financing before revenue reaches a self-sustaining scale.

Limited Commercial Scale And Cost Pressure

Although sales are growing rapidly from a small base, absolute revenue remains insufficient to offset operating expenses and manufacturing overhead. Elevated COGS and inventory reserves also indicate that near-term gross-profit conversion remains difficult as commercialization scales.

Leveraged And Volatile Balance Sheet

Meaningful leverage combined with historically volatile equity levels reduces financial flexibility while the company remains loss-making. This structure can constrain investment in clinical and commercial programs and increase dependence on future financing to support operations.

Humacyte News

HUMA FAQ

What was Humacyte’s price range in the past 12 months?
Humacyte lowest stock price was $0.34 and its highest was $1.53 in the past 12 months.
What is Humacyte’s market cap?
Humacyte’s market cap is $124.51M.
When is Humacyte’s upcoming earnings report date?
Humacyte’s next earnings report is estimated for Nov 10, 2026 (not yet confirmed), which is in 2 days.
How were Humacyte’s earnings last quarter?
Humacyte released its earnings results on Aug 12, 2026. The company reported -$0.16 earnings per share for the quarter, missing the consensus estimate of -$0.113 by -$0.047.
Is Humacyte overvalued?
According to Wall Street analysts Humacyte’s price is currently Undervalued.
Does Humacyte pay dividends?
Humacyte does not currently pay dividends.
What is Humacyte’s EPS estimate?
Humacyte’s EPS estimate is -0.10.
How many shares outstanding does Humacyte have?
Humacyte has 277,798,100 shares outstanding.
What happened to Humacyte’s price movement after its last earnings report?
Humacyte reported an EPS of -$0.16 in its last earnings report, missing expectations of -$0.113. Following the earnings report the stock price went down -6.338%.
Which hedge fund is a major shareholder of Humacyte?
Hedge funds hold Humacyte shares: the largest hedge-fund position in Humacyte is 69,975,760 shares, and hedge funds decreased their holdings by 3.8M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology